Easterly Investment Partners LLC Cuts Stock Holdings in Quanterix Corporation $QTRX

Easterly Investment Partners LLC trimmed its position in shares of Quanterix Corporation (NASDAQ:QTRX) by 50.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 616,681 shares of the company’s stock after selling 635,503 shares during the quarter. Easterly Investment Partners LLC owned 1.32% of Quanterix worth $3,922,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Farther Finance Advisors LLC bought a new position in shares of Quanterix during the 4th quarter worth approximately $26,000. Quarry LP lifted its position in shares of Quanterix by 277,300.0% during the 3rd quarter. Quarry LP now owns 5,548 shares of the company’s stock worth $30,000 after buying an additional 5,546 shares in the last quarter. R Squared Ltd bought a new position in shares of Quanterix during the 3rd quarter worth approximately $64,000. HUB Investment Partners LLC bought a new position in shares of Quanterix during the 2nd quarter worth approximately $81,000. Finally, Brevan Howard Capital Management LP bought a new position in shares of Quanterix during the 2nd quarter worth approximately $96,000. Institutional investors own 86.48% of the company’s stock.

Quanterix Stock Performance

Shares of NASDAQ QTRX opened at $3.06 on Monday. The stock has a fifty day simple moving average of $3.25 and a two-hundred day simple moving average of $5.30. Quanterix Corporation has a 1-year low of $2.39 and a 1-year high of $8.77. The firm has a market cap of $144.16 million, a price-to-earnings ratio of -1.30 and a beta of 1.14.

Quanterix (NASDAQ:QTRX) last released its earnings results on Wednesday, May 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.12. The business had revenue of $35.90 million during the quarter, compared to the consensus estimate of $36.84 million. Quanterix had a negative return on equity of 23.92% and a negative net margin of 71.86%. Analysts forecast that Quanterix Corporation will post -0.97 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have commented on QTRX shares. Weiss Ratings cut shares of Quanterix from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 13th. TD Cowen dropped their target price on shares of Quanterix from $7.00 to $4.00 and set a “hold” rating on the stock in a research report on Thursday, May 7th. Wall Street Zen raised shares of Quanterix from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Canaccord Genuity Group dropped their target price on shares of Quanterix from $8.00 to $4.00 and set a “hold” rating on the stock in a research report on Monday, April 20th. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Reduce” and an average target price of $4.00.

About Quanterix

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.